Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new pneumococcal vaccine called PG4 compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC in children and adolescents. The study aims to see how well the new vaccine helps the body fight germs that cause pneumonia, meningitis, and ear infections. It includes children aged 15 months to less than 18 years, some of whom may have previously received pneumococcal vaccines. Participants will be divided into three age groups 15 months to under 2 years, 2 to under 5 years, and 5 to under 18 years. Within each group, participants will be randomly assigned in a 21 ratio to receive a single injection of either the new vaccine PG4 or the existing 20vPnC vaccine, given in the arm or thigh. The study is conducted across multiple countries including the United States and Puerto Rico. Each participant will be involved for about 6 months, attending two clinic visitsone for vaccination and one for follow-upand one telephone follow-up. Blood samples will be collected at visits to measure immune response, and participants will be monitored for local and systemic reactions, adverse events, and serious adverse events throughout the study period. The study evaluates immune system protein levels and antibody activity one month after vaccination to compare the vaccines effects.